Epidemiological, Microbiological, Clinical, and Prognostic Factors of Bacteremia Caused by High-Level Vancomycin-Resistant Enterococcus Species

PESET V; TALLÓN P; SOLA C; SÁNCHEZ E; SARRIÓN A; PÉREZ-BELLÉS C; VINDEL A; CANTÓN E; GOBERNADO M

Springer-Verlag GmbH

Lugar: Munich, Germany; Año: 2000 vol. 19 p. 742 - 742

case-control study was performed between 1994 and 1996 in order to study the epidemiological, microbiological, clinical, and prognostic features of high-level vancomycin-resistant enterococcal bacteremia. Seventeen consecutive patients who had clinically significant bacteremia due to vancomycin-resistant enterococci (vanA genotype: 16 Enterococcus faecalis, 1 Enterococcus faecium) were compared with 169 who had vancomycin-susceptible enterococcal bacteremia. The following were selected by multivariate analysis as independent risk factors that influenced the development of high-level vancomycin-resistant enterococcal bacteremia: prior glycopeptide therapy (P=0.049); inclusion in a hemodialysis program (P=0.046); prior therapy with corticosteroids or antineoplastic agents (P=0.029); and prior surgical treatment (P=0.022). The following other factors were selected by univariate analysis: tracheostomy (P=0.002); prolonged hospitalization (P=0.01); and any kind of puncture (P=0.02). The c